Atopic Dermatitis

Stigma has a major impact on mental health and quality of life for pediatric patients with chronic skin diseases, according to a study.

Eli Lilly and Company announced a net revenue increase of 26% in the first quarter of 2024 and the resubmission of its biologic license application for lebrikizumab for the treatment of atopic dermatitis, according to a press release.

SelectION announced positive results from its first-in-human phase 1b trial of its lead compound, a selectively-optimized peptide, for the treatment of patients with atopic dermatitis, according to a company press release.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

The FDA has accepted Dermavant Science’s supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged 2 years and older, the company announced in a press release.

AbbVie reported a worldwide net revenue of $12.31 billion in the first quarter of 2024 despite Humira sales dropping due to biosimilar competition, according to a company press release.

Healio has compiled April’s most-read news in dermatology.

Dupilumab demonstrated sustained effectiveness across patientreported outcome measures in adult and pediatric individuals with atopic dermatitis, according to a study.

Incyte and Escient Pharmaceuticals have entered a definitive agreement under which Incyte will acquire Escient for $750 million, the companies announced in a press release.

Adults and adolescents with moderate to severe atopic dermatitis treated with upadacitinib reported year-long improvements in skin symptoms, mental health and quality of life, according to a study.